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Abstract
Two hundred seventy thousand people in the US and 450,000
people in Europe experience out-of-hospital cardiac arrest each
year. Perceived poor prognosis and expense of care of patients
resuscitated from cardiac arrest remain barriers to implementation
of effective therapies. In this issue of Critical Care, Graf and
colleagues have provided a programmatic evaluation of the costs
and consequences of intensive care after resuscitation from
cardiac arrest. Thirty-one percent of the cohort that survived to be
cared for in the intensive care setting were still alive 5 years after
hospital discharge. The health-related quality of life of this group of
5-year survivors was similar to that of matched healthy controls,
and the cost per quality-adjusted life year gained was similar to or
less than the cost of other commonly used medical interventions.
We need to change the culture of resuscitation and recognize that
cardiac arrest is a treatable condition that is associated with
acceptable quality of life and costs of care after resuscitation.
In this issue of Critical Care, Graf and colleagues [1]
describe a long-term cohort study of the costs and conse-
quences of intensive care after resuscitation from cardiac
arrest. We took particular interest in this study because
health care costs in the US exceed those of any other nation.
This study was a programmatic evaluation rather than an
assessment of a specific intervention such as therapeutic
hypothermia. Thirty-one percent of the cohort that survived to
be cared for in the intensive care setting were still alive 5
years after hospital discharge. The health-related quality of life
of this group of 5-year survivors was similar to that of
matched healthy controls. The cost per quality-adjusted life
year (QALY) gained was 14,487 euros (approximately US
$22,900 at current rates). The cost per life year gained
increased by 18% when it included the 6.4% of 5-year
survivors who had severe neurological disability (that is,
Glasgow Coma Scale score of less than 6).
How much to pay for a health intervention is a poignant
question most societies have yet to answer formally. Such
decisions are complex and are predicated not only on the
absolute and incremental cost of the intervention but also on
the quantity and quality of effectiveness data related to the
intervention. Countries with a centralized planning process
for health care may imply their answer when they approve or
disapprove for national formulary a drug designed to extend
life in a terminal disease. The UK’s National Health Service
recently declined approval of bevacizumab (Avastin, with a
cost of therapy per year of approximately $100,000) as first-
line therapy for lung and breast cancer [2]. In the US, there
appears to be a general consensus that $50,000 to
$100,000 per year of life gained is acceptable [3]. An
analysis based on economic principles suggested that we
should be willing to spend up to twice the average annual
income on health care [4]. In this light, less than 15,000
euros per QALY for intensive care after resuscitation from
cardiac arrest is similar to or less than the cost of other
commonly used medical interventions.
This study has some limitations relative to current standards
for economic evaluation of health interventions [5]. It was
performed in a single institution in a single country. The
application of post hoc subgroup analysis based on neuro-
logic status tended to underestimate the costs and over-
estimate the cost-effectiveness of the program. Restricting
the analysis to consider a health care rather than a societal
perspective underestimated costs and made it difficult to
compare the results of this analysis with comprehensive
economic evaluations of health care and other interventions.
However, such limitations are unlikely to change the central
messages of the study. These are that quality of life after
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resuscitation from cardiac arrest is good and that the costs of
care after resuscitation are acceptable.
The study of Graf and colleagues is a timely one. Survival
after out-of-hospital cardiac arrest (OHCA) has been static
over time [6], but a recent analysis suggests that outcomes
are improving [7]. Therapeutic hypothermia [8,9] is likely to
be the first of several effective hospital-based interventions
for cardiac arrest [10-12]. However, adoption of hypothermia
has been slow [13]. The perceived poor prognosis and
expense of care of patients resuscitated from cardiac arrest
are key barriers to the implementation of effective therapies
such as cooling. We need to change the culture of resusci-
tation and recognize that cardiac arrest is a treatable condi-
tion that is associated with good quality of life after
resuscitation as well as acceptable costs of care.
In many countries, a high percentage of health care costs
occur in the last year of life. Imminent death is not always
predictable, and a persistent vegetative state is associated
with poor quality of life. Therefore, we require better methods
of predicting who will recover and who will have disability
after resuscitation from cardiac arrest [14], especially in the
era of hypothermia.
Two hundred seventy thousand people experience OHCA
each year in the US (G. Nichol, unpublished data). About
450,000 do so in Europe based on extrapolation from
population-based incidence estimates [15]. Only 7% of those
with OHCA survive to discharge [16]. If we double survival
after OHCA, then 18,900 premature deaths in the US and
31,500 in Europe would be averted each year. There are
many ways to improve the chain of survival, including
improved communications from citizens to emergency
medical services, delivery of care to the patient, delivery of
the patient to the hospital, and delivery of cardiac and critical
care once there. The time has come for us to come together
to do so.
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